Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations

Trazodone is approved for the treatment of major depressive disorders, marketed as immediate release (IR), prolonged release, and once a day (OAD) formulation. The different formulations allow different administration schedules and may be useful to facilitate patients’ compliance to the antidepressa...

Descripción completa

Detalles Bibliográficos
Autores principales: Oggianu, Laura, Di Dato, Giorgio, Mangano, Giorgina, Rosignoli, Maria Teresa, McFeely, Savannah, Ke, Alice Ban, Jones, Hannah M., Comandini, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200067/
https://www.ncbi.nlm.nih.gov/pubmed/35233913
http://dx.doi.org/10.1111/cts.13253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200067/
https://www.ncbi.nlm.nih.gov/pubmed/35233913
http://dx.doi.org/10.1111/cts.13253

Ejemplares similares